---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-070345"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2026-06-04T12:00:53+00:00"
generated_at: "2026-06-04T12:06:15.878327+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics presents at Jefferies; outlines registrational path for DLB psychosis

## Summary
- Cash ~$31.2M as of March 31, 2026; $25.6M remaining NIA grant funds; runway into Q2 2027.
- SHIMMER Phase 2: 86% slowing of NPI-12 decline vs placebo; 89% slowing of hallucinations/delusions.
- FDA Division of Psychiatry meeting held May 20, 2026; minutes expected June 2026; registrational study design being finalized.
- Registrational plan: 9-month, 1:1 zervimesine 100mg vs placebo, endpoint NPI-2; open-label extension planned.
- START Phase 2 in early Alzheimer's (545 pts) ongoing; topline data expected 2H 2027.

## SEC filing metadata
- accession: 0001104659-26-070345
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2026-06-04T12:00:53+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465926070345/0001104659-26-070345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465926070345/tm2616896d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-070345
- JSON: https://secwatch.observer/filing/0001104659-26-070345.json
- Plain text: https://secwatch.observer/filing/0001104659-26-070345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.